PB1884: ENGAGING INNATE IMMUNITY: A PHASE 1 DOSE ESCALATION STUDY TO ASSESS SAFETY AND TOLERABILITY OF AFM28 MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML)

• Montserrat Arnan,
• Pau Montesinos,
• Stéphane de Botton,
• Christian Recher,
• Lydia Wunderle,
• Michael Emig,
• Andreas Harstrick,
• Kerstin Pietzko,
• Sheena Pinto,
• Paulien Ravenstijn,
• Naval Daver

Affiliations

Montserrat Arnan

1 Institut Català d’Oncologia-Hospital Duran i Reynals, Barcelona, Spain

Pau Montesinos

2 Hospital Universitari i Politècnic La Fe, Valencia, Spain

Stéphane de Botton

3 Institut Gustave Roussy, Villejuif, France

Christian Recher

4 CHU de Toulouse-Institut Universitaire du Cancer Toulouse de Toulouse Oncopole, Toulouse, France

Lydia Wunderle

5 Affimed GmbH, Heidelberg, Germany

Michael Emig

5 Affimed GmbH, Heidelberg, Germany

Andreas Harstrick

5 Affimed GmbH, Heidelberg, Germany

Kerstin Pietzko

5 Affimed GmbH, Heidelberg, Germany

Sheena Pinto

5 Affimed GmbH, Heidelberg, Germany

Paulien Ravenstijn

5 Affimed GmbH, Heidelberg, Germany

Naval Daver

6 The University of Texas MD Anderson Cancer Center, Houston, United States